Ilan Ganot - Mar 2, 2023 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role: Director
Signature: /s/ by David Tyrone Howton as attorney-in-fact for Ilan Ganot
Stock symbol: SLDB
Transactions as of: Mar 2, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/6/2023, 08:20 PM
Previous filing: Jan 31, 2023
Next filing: Jun 8, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SLDB	Common Stock	Options Exercise		+1.58K	+1.87%		86.2K	Mar 2, 2023	Direct	F1, F2
holding	SLDB	Common Stock						19.4K	Mar 2, 2023	See Footnote	F3
holding	SLDB	Common Stock						1.38K	Mar 2, 2023	Wife

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SLDB	Restricted Stock Units	Options Exercise	$0	-1.58K	-25.01%	$0.00	4.75K	Mar 2, 2023	Common Stock	1.58K		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Represents 82,133 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship.
F3	Represents 19,394 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.
F4	On December 2, 2022 (the "Grant Date"), Mr. Ganot was granted 6,333 restricted stock units, vesting in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of a change in control the restricted stock units shall accelerate in full.